Drug Trial Radar · NCT04767373
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,632
Actual
Start
Apr 7, 2021
Primary completion
Jul 9, 2024
Study completion Jul 9, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 1 year
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through 150 postdose compared to placebo.
Conditions
- Respiratory Syncytial Virus Infection
Interventions
ClesrovimabBiological
Clesrovimab solution
PlaceboDrug
Placebo (0.9% sodium chloride \[NaCL\]) solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI)Time frame: From Day 1 (postdose) to Day 150
- RSV Season 1: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)Time frame: From Day 1 (postdose) to Day 5
- RSV Season 1: Percentage of Participants With FeverTime frame: From Day 1 (postdose) to Day 5
- RSV Season 1: Percentage of Participants With Solicited Systemic AEsTime frame: From Day 1 (postdose) to Day 5
- RSV Season 1: Percentage of Participants With Anaphylaxis/Hypersensitivity AE of Special Interest (AESI)Time frame: From Day 1 (postdose) to Day 42
- RSV Season 1: Percentage of Participants With Rash AESITime frame: From Day 1 (postdose) to Day 42
- RSV Season 1: Percentage of Participants With ≥1 Nonserious AETime frame: From Day 1 (postdose) to Day 42
- Percentage of Participants With Serious Adverse Events (SAEs)Time frame: RSV Season 1: Day 1 to Day 365, RSV Season 2: Day 366 to Day 515
Locations
217 sites in 24 countries. Site status is shown where the registry gives one.
Southeastern Pediatric Associates, P.A. ( Site 0008)
Dothan, Alabama
Northwest Arkansas Pediatric Clinic ( Site 0050)
Fayetteville, Arkansas
Children's Clinic of Jonesboro, PA ( Site 0058)
Jonesboro, Arkansas
Long Beach Memorial Medical Center ( Site 0014)
Long Beach, California
Madera Family Medical Group ( Site 0046)
Madera, California
Orange County Research Institute ( Site 0057)
Ontario, California
Children's Hospital Colorado ( Site 0066)
Aurora, Colorado
Optumcare Colorado Springs, LLC ( Site 0022)
Colorado Springs, Colorado
Children's National Hospital ( Site 0076)
Washington D.C., District of Columbia
MedStar Georgetown Pediatrics ( Site 0047)
Washington D.C., District of Columbia
Next Phase Research Alliance, LLC ( Site 0071)
Homestead, Florida
Acevedo Clinical Research Associates ( Site 0002)
Miami, Florida
Tekton Research ( Site 0080)
Chamblee, Georgia
Meridian Clinical Research, LLC ( Site 0083)
Macon, Georgia
Clinical Research Prime ( Site 0075)
Idaho Falls, Idaho
Saltzer Medical Group ( Site 0004)
Nampa, Idaho
Cotton-O'Neil Clinical Research Center PediatricCare ( Site 0061)
Topeka, Kansas
ACC Pediatric Research ( Site 0067)
Haughton, Louisiana
Meridian Clinical Research, LLC ( Site 0082)
Hastings, Nebraska
Midwest Children's Health Research Institute, LLC ( Site 0044)
Lincoln, Nebraska
Dartmouth-Hitchcock Medical Center ( Site 0031)
Lebanon, New Hampshire
Rutgers University-Pediatric Clinical Research Center ( Site 0055)
New Brunswick, New Jersey
Javara - Wake Forest Health Network - Ford, Simpson, Lively & Rice Pediatrics ( Site 0093)
Winston-Salem, North Carolina
Senders Pediatrics ( Site 0062)
Cleveland, Ohio
Ohio Pediatric Research Association ( Site 0063)
Dayton, Ohio
CCP- Kid's Way ( Site 0017)
Hermitage, Pennsylvania
UPMC Children's Hospital of Pittsburgh - Primary Care Center - Oakland ( Site 0043)
Pittsburgh, Pennsylvania
Coastal Pediatric Research ( Site 0013)
Charleston, South Carolina
Tribe Clinical Research, LLC ( Site 0015)
Greenville, South Carolina
Holston Medical Group ( Site 0040)
Kingsport, Tennessee
Javara - Privia Medical Group North Texas - Frisco ( Site 0086)
Frisco, Texas
University of Texas Medical Branch at Galveston ( Site 0059)
Galveston, Texas
DM Clinical Research ( Site 0005)
Houston, Texas
FMC Science - Lampasas ( Site 0011)
Lampasas, Texas
DCOL Center for Clinical Research ( Site 0042)
Longview, Texas
University Health System- San Antonio ( Site 0048)
San Antonio, Texas
Private Practice - Dr. Etokhana ( Site 0089)
San Antonio, Texas
Road Runner Research, Ltd ( Site 0049)
San Antonio, Texas
Alliance for Multispecialty Research, LLC ( Site 0092)
Kaysville, Utah
Wee Care Pediatrics ( Site 0077)
Layton, Utah
Showing 40 of 217 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.